by The Bovine Mastitis Market is estimated to be valued at US$ 1497.52 Mn in 2023 and is expected to exhibit a CAGR of 5.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Bovine mastitis refers to the inflammation of mammary glands in cows. It is majorly caused by bacterial infections during lactation. The predominant bacteria responsible for mastitis include Streptococcus agalactiae, Staphylococcus aureus, and Streptococcus dysgalactiae. Bovine mastitis detection products include somatic cell counters, microbiological culture media, PCR & kits, teat dip solutions, intra-mammary treatment units, and others. These products aid in early and easy diagnosis and treatment of bovine mastitis.
Market key trends:
One of the major trends fueling growth in the Bovine Mastitis Market is the increasing automation in mastitis detection. There is a rise in adoption of technologies such as electronic milk meters, automatic calf feeders and automatic teat sprayers and massagers for mastitis control and prevention. These automated technologies aid in early detection and timely treatment of mastitis in dairy cows. Automation reduces manual errors and improves milking efficiency which positively impacts the milk quality and quantity. The automated technologies also help dairy farmers to focus more on herd management as a whole rather than engaging in regular testing and treatment procedures.
Porter’s Analysis
Threat of new entrants: Low capital requirements and established distribution channels lower barriers to entry for some mastitis products. However, large R&D investments and regulatory hurdles protect incumbents.
Bargaining power of buyers: Dairy producers have significant bargaining power as they can choose from multiple mastitis treatment options. However, their priority is bovine health over price.
Bargaining power of suppliers: Veterinary pharma companies developing new mastitis drugs have some pricing power due to patent protection and specialized R&D expertise. However, alternative therapies constrain this.
Threat of new substitutes: No close substitutes for pharmaceutical mastitis treatments exist currently. Non-drug options like improved hygiene provide partial substitutability.
Competitive rivalry: Intense as established players vigorously defend their product portfolios and market share through ongoing innovation.
SWOT Analysis
Strengths: Established brands, therapeutic expertise, global reach and scale advantages for major players.
Weaknesses: Heavy R&D costs, price pressures from generic competitors, regulation-linked uncertainties.
Opportunities: Expanding dairy output in emerging economies, demand for novel long-acting and vaccine-based products.
Threats: Rising input costs, competition from regional generic drug makers, stringent manufacturing regulations.
Key Takeaways
The global bovine mastitis market is expected to witness high growth, exhibiting CAGR of 5.2% over the forecast period, due to increasing dairy consumption globally especially in Asia Pacific and Latin America. The market size for 2023 is US$ 1497.52 Mn.
The Asia Pacific region dominates the global market with over 35% market share due to rising demand for dairy produce from a growing middle class in India and China. North America is second largest due to major dairy clusters and is set to grow at a CAGR of 4.8% during the forecast period.
Key players operating in the bovine mastitis market are Zoetis, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Bayer AG, Elanco, Ceva, West Way Health, Norbrook, DeLaval, ImmuCell Corporation, Advanced Animal Diagnostics, and Nimrod Veterinary Products Ltd. These companies are focusing on expansion in emerging economies and development of novel product formulations like teat sealants and vaccines.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
